Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
These algorithms can be used in future pharmacoepidemiologic studies to evaluate medications associated with intrahepatic or extrahepatic cholangiocarcinoma.
Authors
- Rebecca A. Hubbard (ORCID: https://orcid.org/0000-0003-0879-0994)
- Maarouf Hoteit (ORCID: https://orcid.org/0000-0001-6053-6884)
- Tamar H. Taddei (ORCID: https://orcid.org/0000-0002-6500-1739)
- Basile Njei (ORCID: https://orcid.org/0000-0003-0714-4368)
- Lesley S. Park (ORCID: https://orcid.org/0000-0002-3848-7753)
- Emma E. Furth (ORCID: https://orcid.org/0000-0002-9309-985X)
- Anya Mezina (ORCID: https://orcid.org/0000-0002-1515-4358)
- Vincent Lo Re (ORCID: https://orcid.org/0000-0001-7955-0600)
- Nicole Ferrante (ORCID: https://orcid.org/0000-0001-8794-9304)
- Kelley Weinfurtner (ORCID: https://orcid.org/0000-0003-1506-232X)
- Debika Bhattacharya (ORCID: https://orcid.org/0000-0002-2136-7763)
- Amit Singal
- Craig Newcomb
- David E. Kaplan
Institutions
- University of California, Los Angeles (US)
- Yale University (US)
- VA Connecticut Healthcare System (US)
- Southwestern Medical Center (US)
- Philadelphia VA Medical Center (US)
- Southwestern Medical Center (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1002/pds.70154
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Veterans Affairs
- National Institute on Alcohol Abuse and Alcoholism
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases